Gedeon Richter Media Richter publishes Q1-Q3 2026 results
Richter publishes Q1-Q3 2026 results
10/11/2026
Upgraded full-year guidance on strong YTD delivery
  • CER Pharma revenues grew by 11.7%, driven by very strong BIO and CNS and double-digit WHC growth. Reported Pharma revenues rose by 2.6% YoY to HUF 686.5bn in Q1-Q3 2026, affected by c. -9ppt currency headwind.
  • CER Clean EBIT (pharma) growth was outstanding at 25%, as BIO is now close to be breaking even, cariprazine continues to impress and efficiency initiatives result in structurally lower opex; reported Clean EBIT (pharma) grew by 8% to HUF 229.9bn.
  • Net profit was HUF 174.9bn in Q1-Q3 2026, rising by 7% YoY, driven by solid operating profits. Free Cash Flow was 12% higher YoY to HUF 223bn.
  • 2026 Revenue guidance (at constant exchange rates, CER) is upgraded to above 10% growth, while Clean EBIT guidance (CER) is now upgraded to high-teens growth on the back of the strong YTD delivery.

 

Budapest, 10 November 2026 - Gedeon Richter Plc. (“Richter”) announced today its Q3/Q1-Q3 2026 financial results.

CER (constant exchange rate) Pharma revenues rose by 11.7% in Q1-Q3 2026, slightly above the high-single-digit growth guidance for the year, with growth further accelerating in Q3, supported by a low Q3 base. FX remained a major headwind with c. -9ppt negative impact on reported revenues in both Q3 and Q1-Q3 (primarily due to the strong HUF). Hence, reported Pharma revenues were 2.6% higher at HUF 686.5bn in Q1-Q3 2026.   

  • CNS revenues were 19% higher (CER) in Q1-Q3 2026 YoY, on the back of relentless strength in Vraylar® (AbbVie’s net sales increased by 17% YoY to USD 3.04bn as performance in both bipolar disorder and adjunctive MDD remained very strong) and jumping Reagila® sales (+37% CER), driven by some high-performing countries (in both Richter and partner territories) and also by delivery schedules.
  • Women’s Healthcare sales growth accelerated further in Q3 (+19% CER, from a low year-ago base), bringing Q1-Q3 CER revenue growth to 11%. In Q3 sales grew in all regions and all therapeutic segments (including traditional OCs), with Ryeqo®, Lenzetto® and Drovelis® being the key growth drivers YTD.
  • BIO revenues jumped in Q1-Q3 (+35% CER), as both biosimilars (strong teriparatide sales and new product launches) and CDMO revenues contributed to the growth.
  • GenMed revenues rose by 1% in Q1-Q3 YoY (CER), as dynamics improved further in Q3 with sales rebounding strongly (+17% CER) from a rather weak year ago level. Core therapeutic areas (TAs) exhibited stable, improving trends, while the YTD weakness in OTC and non-strategic TAs remain a major derailer of GenMed performance in 2026.

Gross profit (pharma, net of restructuring charges) rose by 2.5% YoY to HUF 474.5bn in Q1-Q3 2026; gross margin declined to 69.1% (-0.1ppt).

CER Clean EBIT (pharma) growth was outstanding at 25% in Q1-Q3 2026, tracking ahead of the previous guidance. The much narrowing losses in BIO, the outperformance of cariprazine, and continued strong opex discipline (lower costs) all contributed to improving profitability. Reported Clean EBIT (pharma) increased by 8% to HUF 229.9bn, the gap to CER growth explained by the persisting FX headwind.

Reported EBIT reached HUF 216.8bn in Q1-Q3 2026, rising by 6% YoY.

Net profit (attributable to the owners of the parent) was HUF 174.9bn in Q1-Q3 2026, increasing by 7.1% YoY, reflecting stronger operating profits, as net financial expenses remained broadly unchanged compared to last year’s.

Free cash flow (before M&A) reached a record-high HUF 223bn in Q1-Q3 2026, up 12% YoY, driven by higher operating profits and lower Net Working Capital funding need.

 

Gábor Orbán, CEO commented the results:

“The strong Q3 delivery makes us further upgrade our full-year guidance to above 10% revenue growth and Clean EBIT growth in the high-teens (both CER). With 35% YTD revenue growth, breaking even in BIO is now within reach; cariprazine does not stop impressing; and Women’s Healthcare is growing double-digit on the back of outstanding growth of Ryeqo® and Lenzetto®. We are witnessing a paradigm shift in hormone therapies, which is now translating into surging demand for menopause treatments, boding well for the launch of our new original product, Fylrevy®, one of the focus projects for 2026 and beyond.”

 

About Gedeon Richter Plc.

Richter aspires to be a global innovator in some key scientific fields, while dedicated to making medicines more accessible worldwide. Founded in 1901, headquartered in Hungary, with a market capitalization of EUR 4.8bn and sales of EUR 2.3bn in 2025, it operates Central Europe's largest R&D hub. Its research drives breakthroughs in Neuropsychiatry and Women's Healthcare, while Biotechnology and General Medicines strengthen its affordable treatment portfolio. Committed to sustainable growth, Richter invests in R&D, manufacturing excellence, and digitalization to advance medical innovation. Learn more at www.gedeonrichter.com

 

For further information:

Investors:        Róbert Réthy, CFA                                                                +36 20 342 2555

Media:               Zsuzsa Beke                                                                           +36 20 916 4507